SK10422001A3 - 2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepín-3-hydroxámové kyseliny ako inhibítory metaloproteináz medzibunkovej hmoty - Google Patents

2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepín-3-hydroxámové kyseliny ako inhibítory metaloproteináz medzibunkovej hmoty Download PDF

Info

Publication number
SK10422001A3
SK10422001A3 SK1042-2001A SK10422001A SK10422001A3 SK 10422001 A3 SK10422001 A3 SK 10422001A3 SK 10422001 A SK10422001 A SK 10422001A SK 10422001 A3 SK10422001 A3 SK 10422001A3
Authority
SK
Slovakia
Prior art keywords
alkyl
carbon atoms
group
moiety
tetrahydro
Prior art date
Application number
SK1042-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Jay Donald Albright
Santos Efren Guillermo Delos
Jeremy Ian Levin
James Ming Chen
Original Assignee
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Company filed Critical American Cyanamid Company
Publication of SK10422001A3 publication Critical patent/SK10422001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
SK1042-2001A 1999-01-27 2000-01-27 2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepín-3-hydroxámové kyseliny ako inhibítory metaloproteináz medzibunkovej hmoty SK10422001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908099A 1999-01-27 1999-01-27
PCT/US2000/001991 WO2000044730A1 (en) 1999-01-27 2000-01-27 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
SK10422001A3 true SK10422001A3 (sk) 2002-09-10

Family

ID=22900512

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1042-2001A SK10422001A3 (sk) 1999-01-27 2000-01-27 2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepín-3-hydroxámové kyseliny ako inhibítory metaloproteináz medzibunkovej hmoty

Country Status (25)

Country Link
EP (1) EP1147095B1 (id)
JP (1) JP2002535392A (id)
KR (1) KR20010101730A (id)
CN (1) CN1197849C (id)
AR (1) AR022423A1 (id)
AT (1) ATE273288T1 (id)
AU (1) AU767039B2 (id)
BG (1) BG105736A (id)
BR (1) BR0007759A (id)
CA (1) CA2356267A1 (id)
CZ (1) CZ20012637A3 (id)
DE (1) DE60012883T2 (id)
EA (1) EA200100809A1 (id)
ES (1) ES2223470T3 (id)
HU (1) HUP0105302A3 (id)
ID (1) ID29046A (id)
IL (1) IL144168A0 (id)
NO (1) NO20013675L (id)
NZ (1) NZ511885A (id)
PL (1) PL349025A1 (id)
PT (1) PT1147095E (id)
SK (1) SK10422001A3 (id)
TR (1) TR200102131T2 (id)
WO (1) WO2000044730A1 (id)
ZA (1) ZA200104321B (id)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6770647B2 (en) 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
CA2464727A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US7488754B2 (en) 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
AU2003253176A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
JP5069108B2 (ja) * 2004-07-21 2012-11-07 メルク セローノ ソシエテ アノニム オクタヒドロピロロ［２，３，ｃ］ピリジン誘導体と、その医薬としての利用法
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
FR2950056B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950057B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
SG186795A1 (en) 2010-07-08 2013-02-28 Kaken Pharma Co Ltd N-hydroxyformamide derivative and medicament containing same
KR101836547B1 (ko) * 2010-09-17 2018-04-19 고쿠리츠다이가쿠호우진 도쿄다이가쿠 혈소판의 기능을 유지하기 위한 조성물
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
CA3151199A1 (en) * 2019-09-19 2021-03-25 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ES2153031T4 (es) * 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
PT861236E (pt) * 1995-11-13 2002-07-31 Hoechst Ag Acidos alfa-iminohidoxamicos e carboxilicos n-substituidos ciclicos e heterociclicos
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
CN1542002A (zh) * 1995-12-08 2004-11-03 ������ҩ�����޹�˾ 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
TR199900382T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Heterosiklik metaloproteaz inhibit�rleri.
ATE227274T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble 1,3-diheterozyklische metalloprotease inhibitoren
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
CN1293663A (zh) * 1998-01-27 2001-05-02 美国氰胺公司 为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂䓬－3－异羟肟酸

Also Published As

Publication number Publication date
AU3216000A (en) 2000-08-18
CN1337952A (zh) 2002-02-27
KR20010101730A (ko) 2001-11-14
EP1147095A1 (en) 2001-10-24
IL144168A0 (en) 2002-05-23
DE60012883T2 (de) 2005-08-25
JP2002535392A (ja) 2002-10-22
NO20013675L (no) 2001-09-21
TR200102131T2 (tr) 2001-12-21
EP1147095B1 (en) 2004-08-11
ID29046A (id) 2001-07-26
AR022423A1 (es) 2002-09-04
HUP0105302A3 (en) 2002-09-30
EA200100809A1 (ru) 2002-02-28
PT1147095E (pt) 2004-12-31
DE60012883D1 (de) 2004-09-16
HUP0105302A2 (hu) 2002-07-29
ES2223470T3 (es) 2005-03-01
PL349025A1 (en) 2002-07-01
ATE273288T1 (de) 2004-08-15
BR0007759A (pt) 2001-11-13
BG105736A (en) 2002-05-31
ZA200104321B (en) 2002-08-26
CN1197849C (zh) 2005-04-20
WO2000044730A1 (en) 2000-08-03
AU767039B2 (en) 2003-10-30
NZ511885A (en) 2003-06-30
CZ20012637A3 (cs) 2002-04-17
CA2356267A1 (en) 2000-08-03
NO20013675D0 (no) 2001-07-26

Similar Documents

Publication Publication Date Title
SK10422001A3 (sk) 2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepín-3-hydroxámové kyseliny ako inhibítory metaloproteináz medzibunkovej hmoty
US5929097A (en) Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU734834B2 (en) Heterocyclic metalloprotease inhibitors
US6150370A (en) 1,3-diheterocyclic metalloprotease inhibitors
EP1432700B1 (en) Spiro-hydantoin compounds useful as anti-inflammatory agents
CZ292942B6 (cs) Derivát (N-hydroxykarbamoyl)-1-(4-fenoxy)benzensulfonylu
JP2000516252A (ja) １，４―複素環式メタロプロテアーゼ阻害剤
EP0927183B1 (en) Spirocyclic metalloprotease inhibitors
SG188642A1 (en) Matrix metalloproteinase inhibitors
JP2013538821A (ja) マトリックスメタロプロテイナーゼ阻害剤
US6071903A (en) 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
RU2174513C2 (ru) Четырехзамещенные производные имидазола, способы их получения, промежуточные соединения и фармацевтическая композиция
JP2002501056A (ja) マトリクス金属プロテイナーゼ阻害薬としての２，３，４，５−テトラヒドロ−１ｈ−［１，４］−ベンゾジアゼピン−３−ヒドロキサム酸
CZ20031804A3 (cs) Inhibitory farnesyltransferázy
US6544984B1 (en) 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
EP0162217A1 (de) 1,2,4-Triazacycloalkadienderivate
MXPA01007575A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
JP2003524000A (ja) オルト−スルホンアミドアリールヒドロキサム酸、それらの製造方法およびマトリックスメタロプロテイナーゼ阻害薬としてのそれらの使用
CZ20002757A3 (cs) 2.3.4.5-tetrahydro-lH/l,4/-benzodiazepin-3- hydroxamové kyseliny